不稳定型心绞痛与PAI-1及血小板活性的临床研究

The clinical research of plasminogen activator inhibitor type-1 and platelet activity in elderly patients with unstable angina pectoris

目的 探讨老年不稳定型心绞痛 (UAP)与纤溶酶原激活物抑制剂 1型 (PAI 1)及血小板活化功能的临床意义。 方法 测定 87例老年UAP患者发作时的血清PAI 1水平与血小板活化因子CD62p活性 ,并与 89例健康对照组比较。 结果 UAP组的PAI 1的水平 (99.77± 3 2 .95 ) μg·L-1较对照组 (5 5 .0 0± 2 1.2 3 ) μg·L-1明显升高 (P <0 .0 1) ;而CD62p活性 (12 .5 6± 4.66) %较对照组 (6.3 3± 2 .3 8) %也有显著升高 (P <0 .0 1)。 结论 老年不稳定型心绞痛的发作与PAI 1水平和血小板活性增高有密切联系。

Objective To study the relationship of plasminogen activator inhibitor type 1(PAI 1) to platelet activity in elderly patients with unstable angina pectoris(UAP). Methods Blood plasma PAI 1 and CD62p (cluster of differentiation 62p) were analyzed in 87 elderly patients with UAP and 89 controls. Results The PAI 1 level was significantly higher in patients with UAP[(99.77±32.95)μg·L -1 ] than that in controls [(55.00±21.23)μg·L -1 ]( P <0.01); The CD62p activity was significantly higher in patients with UAP[(12.56±4.66)%] than that in controls[(6.33±2.38)%]( P <0.01). Conclusions The increases of PAI 1 level and CD62p activation were associated with the pathogenesis of UAP in elderly patients.